Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
Geyer CE Jr, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, Hopkins JO, O'Shaughnessy JA, Rastogi P, Puhalla SL, Hilton CJ, Dang CT, Gómez HL, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Colangelo LH, Swain SM, Mamounas EP, Wolmark N. Geyer CE Jr, et al. Among authors: puhalla sl. J Clin Oncol. 2024 Apr 20;42(12):1344-1349. doi: 10.1200/JCO.23.01428. Epub 2024 Feb 9. J Clin Oncol. 2024. PMID: 38335467
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors.
Maguire WF, Schmitz JC, Scemama J, Czambel K, Lin Y, Green AG, Wu S, Lin H, Puhalla S, Rhee J, Stoller R, Tawbi H, Lee JJ, Wright JJ, Beumer JH, Chu E, Appleman LJ; ETCTN-9153 Study Team. Maguire WF, et al. Cancer Chemother Pharmacol. 2021 Oct;88(4):643-654. doi: 10.1007/s00280-021-04317-y. Epub 2021 Jun 23. Cancer Chemother Pharmacol. 2021. PMID: 34164713 Free PMC article. Clinical Trial.
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP. Isakoff SJ, et al. Future Oncol. 2017 Feb;13(4):307-320. doi: 10.2217/fon-2016-0412. Epub 2016 Oct 14. Future Oncol. 2017. PMID: 27739325 Free PMC article. Clinical Trial.
Phase I study of veliparib in combination with gemcitabine.
Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Stoller R, et al. Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. Epub 2017 Aug 2. Cancer Chemother Pharmacol. 2017. PMID: 28770300 Free PMC article. Clinical Trial.
Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
Niu J, Scheuerell C, Mehrotra S, Karan S, Puhalla S, Kiesel BF, Ji J, Chu E, Gopalakrishnan M, Ivaturi V, Gobburu J, Beumer JH. Niu J, et al. J Clin Pharmacol. 2017 Aug;57(8):977-987. doi: 10.1002/jcph.892. Epub 2017 Apr 7. J Clin Pharmacol. 2017. PMID: 28387939 Free PMC article. Clinical Trial.
Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.
Tawbi H, Christner SM, Lin Y, Johnson M, Mowrey ET, Cherrin C, Chu E, Lee JJ, Puhalla S, Stoller R, Appleman LR, Miller BM, Beumer JH. Tawbi H, et al. Cancer Chemother Pharmacol. 2014 Jan;73(1):207-11. doi: 10.1007/s00280-013-2337-0. Epub 2013 Oct 30. Cancer Chemother Pharmacol. 2014. PMID: 24170263 Free PMC article. Clinical Trial.
80 results